Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Valeant launches new Parkinson’s treatment in US
Zelapar is the first Parkinson’s disease treatment to use a novel oral delivery system called Zydis technology, which allows the tablets to dissolve within seconds in the mouth
Zelapar is the first Parkinson’s disease treatment to use a novel oral delivery system called Zydis technology, which allows the tablets to dissolve within seconds in the mouth
Roche will fund the research, which will be conducted by both Roche and Emisphere. Financial terms of the agreement were not disclosed. Emisphere’s eligen technology is used to
The expanded trial was prompted by encouraging interim safety and efficacy data recently reported for single-dose administration of CG0070 and will include up to 45 additional patients who
Researchers at Harvard’s Beth Israel Deaconess Medical Center (BIDMC) will attempt to verify the pharmacokinetic and pharmacological properties of PT-401, DNAPrint’s lead product in development. “We expect that
REP8839 is being developed in combination with mupirocin, a widely used topical antibiotic. The study will examine various concentrations of REP8839 alone and in combination with mupirocin versus
Under the agreement, DAC will access compound intellectual property that Evotec has generated on this disease target through its internal R&D activities. The aim of the collaboration will
Astellas started phase II trials of the drug in the US and Canada but has halted these trials in light of the interim findings. In more positive news
Aerugen, which was being evaluated for its ability to prevent Pseudomonas aeruginosa infection in cystic fibrosis patients, did not live up to the efficacy results indicated in an
The inclusion of Japan in the deal gives Astellas worldwide rights to this potential treatment for serious infections. Under the extended licensing deal, US-based Theravance will receive an
Non-alcoholic steatohepatitis (NASH) is one stage in a disease spectrum that ranges from simple fatty liver, or steatosis, to steatohepatitis, advanced fibrosis, and end-stage cirrhosis. There is no